Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.76
-$0.06(-7.45%)
At close: 4:00 PM EDT
$0.76
-$0.06(-7.45%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous Close$0.71
Volume201.26K
Average Volume (3M)71.94K
Market Cap
$23.05M
Enterprise Value$8.20
Total Cash (Recent Filing)$18.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Nov 18, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding34,141,460
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.74
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Favorable FDA Safety Review Allows Dosing To ResumeA no-comments FDA safety review is a durable de-risking event: it validates the company’s safety monitoring and protocol changes, enables continuation of clinical programs across indications, and preserves the ability to generate pivotal data and regulatory feedback over the next 2–6 months.
Private Placement Extends Operating RunwayNew gross proceeds that extend runway into 2H 2027 materially increase the company’s ability to fund planned Phase 1b and IND-enabling work without immediate capital markets access, supporting program execution and reducing short-term financing disruption risk.
Improving Loss Trend And Stabilized BurnA multi-year narrowing of net losses and more stable TTM cash burn suggests improving cost discipline and operational efficiency. That trend increases predictability of funding needs and supports executing clinical milestones with lower incremental cash requirements.
Bears Say
Negative Stockholders’ Equity Weakens Balance SheetNegative equity is a persistent structural weakness that reduces financial flexibility, may limit borrowing capacity, and signals cumulative losses have eroded capital. Over the medium term this raises the company’s dependence on dilutive financings and constrains strategic options.
Sustained Heavy Cash Burn And No RevenueConsistent ~-$21M annual operating cash burn with no product revenue creates an enduring financing requirement. This structural cash gap means program continuity depends on repeated external funding, increasing execution risk if markets or investor appetite tighten.
High Dilution Risk From Loan Amendments And WarrantsContractual expansion of lender conversion rights, repriced and new warrants, and large warrant overhang from the placement create a durable dilution overhang. This can erode existing equity value, complicate future financings, and affect long-term shareholder returns even if clinical milestones are met.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $23.05M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Nov 18, 2026 which is in 92 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Aug 11, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.285 by -$0.165.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Overvalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.26.
How many shares outstanding does CalciMedica have?
CalciMedica has 34,141,460 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.285. Following the earnings report the stock price went down -0.303%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CALC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
20.13% Insiders
0.73% Mutual Funds
26.44% Other Institutional Investors
52.44% Public Companies and
Individual Investors